Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points

Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.:

Source: Neurology Read More

Previous PostRemote Screening for Early Alzheimer’s Holds Promise Amid Key Challenges
Next PostOverviewing Design and Topline Data From Phase 3 APOLLOE4 Study of Valiltramiprosate in Alzheimer Disease: Anton Porsteinsson, MD

Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points

Previous PostRemote Screening for Early Alzheimer’s Holds Promise Amid Key Challenges

Next PostOverviewing Design and Topline Data From Phase 3 APOLLOE4 Study of Valiltramiprosate in Alzheimer Disease: Anton Porsteinsson, MD

Related Posts

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

Categories